Fox Run Management L.L.C. Makes New $778,000 Investment in ANI Pharmaceuticals, Inc. $ANIP

Fox Run Management L.L.C. bought a new stake in shares of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) during the 3rd quarter, HoldingsChannel reports. The institutional investor bought 8,490 shares of the specialty pharmaceutical company’s stock, valued at approximately $778,000.

A number of other institutional investors and hedge funds also recently made changes to their positions in ANIP. GAMMA Investing LLC increased its holdings in shares of ANI Pharmaceuticals by 9.1% during the 3rd quarter. GAMMA Investing LLC now owns 1,505 shares of the specialty pharmaceutical company’s stock valued at $138,000 after acquiring an additional 126 shares during the last quarter. Illinois Municipal Retirement Fund boosted its position in ANI Pharmaceuticals by 1.7% during the third quarter. Illinois Municipal Retirement Fund now owns 8,538 shares of the specialty pharmaceutical company’s stock worth $782,000 after purchasing an additional 145 shares during the period. Amalgamated Bank boosted its position in ANI Pharmaceuticals by 3.1% during the third quarter. Amalgamated Bank now owns 5,066 shares of the specialty pharmaceutical company’s stock worth $464,000 after purchasing an additional 154 shares during the period. CANADA LIFE ASSURANCE Co grew its holdings in ANI Pharmaceuticals by 1.0% during the second quarter. CANADA LIFE ASSURANCE Co now owns 19,408 shares of the specialty pharmaceutical company’s stock valued at $1,267,000 after purchasing an additional 198 shares during the last quarter. Finally, Hantz Financial Services Inc. raised its position in shares of ANI Pharmaceuticals by 202.6% in the third quarter. Hantz Financial Services Inc. now owns 354 shares of the specialty pharmaceutical company’s stock valued at $32,000 after purchasing an additional 237 shares during the period. Institutional investors and hedge funds own 76.05% of the company’s stock.

Analyst Upgrades and Downgrades

Several analysts recently issued reports on the stock. Barclays initiated coverage on shares of ANI Pharmaceuticals in a report on Tuesday, December 9th. They set an “overweight” rating and a $100.00 price objective for the company. Zacks Research lowered shares of ANI Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, January 6th. Guggenheim upped their price target on shares of ANI Pharmaceuticals from $115.00 to $124.00 and gave the company a “buy” rating in a report on Friday, January 16th. Finally, Weiss Ratings reaffirmed a “hold (c+)” rating on shares of ANI Pharmaceuticals in a research report on Monday, December 29th. Six analysts have rated the stock with a Buy rating and three have given a Hold rating to the stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $103.43.

ANI Pharmaceuticals Trading Up 1.1%

Shares of ANIP stock opened at $77.15 on Friday. The firm has a market capitalization of $1.73 billion, a P/E ratio of 47.33 and a beta of 0.50. ANI Pharmaceuticals, Inc. has a 1 year low of $54.56 and a 1 year high of $99.50. The firm’s fifty day simple moving average is $80.37 and its 200 day simple moving average is $86.47. The company has a current ratio of 2.58, a quick ratio of 2.04 and a debt-to-equity ratio of 1.20.

Insider Activity at ANI Pharmaceuticals

In related news, VP Meredith Cook sold 500 shares of the stock in a transaction dated Tuesday, January 13th. The shares were sold at an average price of $84.33, for a total value of $42,165.00. Following the completion of the sale, the vice president owned 74,374 shares in the company, valued at approximately $6,271,959.42. This trade represents a 0.67% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Renee P. Tannenbaum sold 1,800 shares of ANI Pharmaceuticals stock in a transaction dated Friday, December 5th. The stock was sold at an average price of $81.15, for a total value of $146,070.00. Following the sale, the director directly owned 25,157 shares in the company, valued at approximately $2,041,490.55. This trade represents a 6.68% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last quarter, insiders have sold 13,459 shares of company stock worth $1,066,611. 11.10% of the stock is owned by company insiders.

ANI Pharmaceuticals Profile

ANI Pharmaceuticals, Inc is a United States–based specialty pharmaceutical company focused on the development, manufacturing and commercialization of generic and branded prescription drugs. The company operates as an end-to-end provider, offering services that range from active pharmaceutical ingredient (API) production and formulation development to finished dosage form manufacturing and packaging.

ANI’s product portfolio encompasses injectable and oral therapies across several therapeutic areas, including endocrinology, oncology, pain management and respiratory care.